Skip to main content
HCPCS J9035 · Level II · Part B drug

J9035: bevacizumab (Avastin), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J9035

Billing unit
10 MG
Bevacizumab injection
ASP payment limit
$75.492
October 2026; +0.9% vs July 2026
Practitioner MUE
230
MAI 3
OPPS status
SI K
APC 9214
NCCI exposure
no PTP pairs
Coverage articles
1
5 states

TL;DR

HCPCS J9035 is the Level II code for Injection, bevacizumab, 10 mg, billed per 10 MG. The Medicare Part B ASP payment limit for October 2026 is $75.492 per billing unit, up 0.9% from July 2026. The practitioner MUE allows up to 230 units per date of service (MAI 3), so a full 230-unit day is $17,363.16 at the current limit. Under OPPS it carries status indicator K in APC 9214. The 10 mg billing unit means doses are reported in multiples of ten milligrams, with any remainder rounded per contractor policy; mismatched units against the NDC quantity trigger MUE and NDC-unit edits. Other HCPCS codes whose descriptor names bevacizumab: Q5160 (biosimilar bevacizumab-nwgd (Jobevne) from Biocon Biologics Inc); Q5129 (biosimilar bevacizumab-adcd (Vegzelma) from Celltrion USA, Inc); Q5126 (biosimilar bevacizumab-maly (Alymsys)); Q5118 (biosimilar bevacizumab-bvzr (Zirabev) from Pfizer Inc); Q5107 (biosimilar bevacizumab-awwb (Mvasi) from Amgen Inc); C9257 (billed per 0.25 mg). The ASP crosswalk maps 2 NDCs to it, sold as Avastin by Genentech, Inc. 1 Medicare coverage article lists the code across 5 states, including A52370.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9035 at $75.492 per 10 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $74.823 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9035
QuarterPayment limitPerCoinsurance
October 2026$75.49210 MG20%
July 2026$74.82310 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 2 NDCs from 1 labeler to J9035. Report the NDC in the claim's drug segment and bill the number of J9035 units that equals the quantity administered divided by 10 MG; the last column gives units per full package.

NDCs that crosswalk to J9035
NDCDrug nameLabelerPackage sizeBilling units / package
50242-0060-01AvastinGenentech, Inc.4 × 110
50242-0061-01AvastinGenentech, Inc.16 × 140

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for J9035. For practitioners the limit is 230 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9035 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services2303 Date of Service Edit: ClinicalCMS Policy
Facility outpatient hospital2303 Date of Service Edit: ClinicalCMS Policy

MUE for J9035 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9035 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J9035 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J9035 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists J9035 in their HCPCS tables, covering 5 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J9035
ArticleTitleContractor(s)StatesRelated LCD
A52370Billing and Coding: Bevacizumab and biosimilarsWellpoint FederalCT IL MN NY WIL33394

Diagnoses Medicare contractors cover for J9035

One billing and coding article attaches a covered diagnosis list to J9035: 458 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for J9035
ICD-10-CMDescription (FY2027)Articles covering
C17.0Malignant neoplasm of duodenum1 of 1
C17.1Malignant neoplasm of jejunum1 of 1
C17.2Malignant neoplasm of ileum1 of 1
C17.3Meckel's diverticulum, malignant1 of 1
C17.8Malignant neoplasm of overlapping sites of small intestine1 of 1
C17.9Malignant neoplasm of small intestine, unspecified1 of 1
C18.0Malignant neoplasm of cecum1 of 1
C18.1Malignant neoplasm of appendix1 of 1
C18.2Malignant neoplasm of ascending colon1 of 1
C18.3Malignant neoplasm of hepatic flexure1 of 1
C18.4Malignant neoplasm of transverse colon1 of 1
C18.5Malignant neoplasm of splenic flexure1 of 1
C18.6Malignant neoplasm of descending colon1 of 1
C18.7Malignant neoplasm of sigmoid colon1 of 1
C18.8Malignant neoplasm of overlapping sites of colon1 of 1
443 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J9035 are counted here: a group whose instructions name J9035, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J9035, by article
ArticleContractorGroups that applyCovered codes for J9035Full list
A52370Wellpoint Federalgroups 1 and 2 apply to J9035458On LCD L33394

Local coverage policies that list J9035

1 active Local Coverage Determination lists J9035 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J9035 carries status indicator K and is assigned to APC 9214, with a published national unadjusted payment of $75.492. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J9035 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $75.49 per 10 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J9035 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J9035

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J9035

What does HCPCS code J9035 describe?

J9035 is defined by CMS as "Injection, bevacizumab, 10 mg". Each billing unit represents 10 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J9035 a CPT code?

No. J9035 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as bevacizumab (Avastin); CPT codes are five-character codes maintained by the AMA. On a Part B claim J9035 reports the drug itself in 10 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J9035 in October 2026?

The ASP-based payment limit is $75.492 per 10 MG, with 20% beneficiary coinsurance. The July 2026 limit was $74.823. Commercial payers use their own fee schedules.

How many units of J9035 can be billed per day?

The practitioner Medically Unlikely Edit is 230 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "CMS Policy" as the rationale.

Which NDCs map to J9035?

The October 2026 ASP crosswalk lists 2 NDCs from 1 labeler: Avastin (Genentech, Inc.). For example NDC 50242-0060-01 (package size 4) equals 10 billing units of J9035.

Does J9035 have NCCI bundling edits?

No active practitioner PTP pairs list J9035 as a column-1 or column-2 code in the v323r0 release.

J9035 vs Q5160: what is the difference?

Both are HCPCS Level II codes whose descriptor names bevacizumab. What sets Q5160 apart: biosimilar bevacizumab-nwgd (Jobevne) from Biocon Biologics Inc. J9035 is billed per 10 mg, limit $75.492, MUE 230; Q5160 is billed per 10 mg, limit $82.139, MUE 230. Report the code whose descriptor matches the product and setting in the record.

J9035 vs Q5129: what is the difference?

Both are HCPCS Level II codes whose descriptor names bevacizumab. What sets Q5129 apart: biosimilar bevacizumab-adcd (Vegzelma) from Celltrion USA, Inc. J9035 is billed per 10 mg, limit $75.492, MUE 230; Q5129 is billed per 10 mg, limit $21.139, MUE 230. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention J9035?

1 current Billing and Coding Article in the Medicare Coverage Database lists J9035, covering 5 states: A52370 (Billing and Coding: Bevacizumab and biosimilars).

What diagnosis codes support J9035?

One Medicare billing and coding article lists 458 covered ICD-10-CM codes for J9035, for example C17.0 (Malignant neoplasm of duodenum); C17.1 (Malignant neoplasm of jejunum); C17.2 (Malignant neoplasm of ileum); C17.3 (Meckel's diverticulum, malignant); C17.8 (Malignant neoplasm of overlapping sites of small intestine). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.